The National Institute for Health and Care Excellence (NICE) has recommended Cosentyx (secukinumab) as an option for treating moderate to severe plaque psoriasi 6 September 2021
Boston, USA-based non-profit The Institute for Clinical and Economic Review (ICER) has released its final report into the cost-effectiveness of a range of atopi 18 August 2021
The China National Medical Products Administration (NMPA) has further approved Cosentyx (secukinumab) for the treatment of moderate-to-severe plaque psoriasis i 17 August 2021
The UK’s National Institute for Health and Care Excellence (NICE) has issued a Final Appraisal Determination recommending UCB’s (Euronext: UCB) bimekizumab as a 3 August 2021
ParaPRO, a specialty pharma company focused on innovative anti-parasitic treatments, has announced the availability of Natroba (spinosad) Topical Suspension, 0. 3 August 2021
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.